Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fesoterodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.90 |
| ▸ | CHRM3 known ✓ | P20309 | 10/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fesoterodine SCHEMBL31043343 | 1.00 | CHRM2 (0.90) | CHRM2CHRM1KDM4EPOLBCHRM3 | |
| Fesoterodine SCHEMBL814971 | 1.00 | CHRM2 (0.90) | CHRM2CHRM1KDM4EPOLBCHRM3 | |
| Fesoterodine SCHEMBL1993632 | 1.00 | CHRM2 (0.90) | CHRM2CHRM1KDM4EPOLBCHRM3 | |
| Fesoterodine SCHEMBL29366015 | 0.95 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| Fesoterodine SCHEMBL121127 | 0.95 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| Fesoterodine SCHEMBL15148766 | 0.95 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| Fesoterodine SCHEMBL1808421 | 0.95 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| Fesoterodine SCHEMBL812986 | 0.95 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| Fesoterodine SCHEMBL3688110 | 0.94 | CHRM2 (0.98) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| Fesoterodine SCHEMBL2474276 | 0.94 | CHRM2 (0.98) | CHRM2CHRM1CHRM3CHRM5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113750884-A | Mixing equipment for medicinal composition | 合肥信风科技开发有限公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-110151720-B | Pharmaceutical composition containing fesoterodine and preparation method thereof | 合肥信风科技开发有限公司 | 2019-12-17 | — | — | CN | disclosed |
| US-20110152227-A1 | DEUTERIUM LABELLED DERIVATIVES OF 3-(2-HYDROXY-5-METHYPHENYL)-N,N-DIISOPROPYL-3-PHENYLPROPYLAMINE AND METHODS OF USE THEREOF | CONCERT PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152227-A1 | DEUTERIUM LABELLED DERIVATIVES OF 3-(2-HYDROXY-5-METHYPHENYL)-N,N-DIISOPROPYL-3-PHENYLPROPYLAMINE AND METHODS OF USE THEREOF | ADRB3, CHRM3, QDPR | CHRM2 19/4885CHRM3 2/4885CHRM1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.